Hubei Biocause Pharmaceutical Co., Ltd.

000627

CNE000000F48

Life & Health Insurance

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-05-09 pm EDT			5-day change	1st Jan Change
2.31 ^CNY	0.00%		-2.94%	-18.66%

Apr. 29	Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 15	Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Hubei Biocause Pharmaceutical Co., Ltd. Approves Final Cash Dividend for the Year 2020, Payable 04 June 2021

May 28, 2021 at 03:38 pm EDT

Hubei Biocause Pharmaceutical Co., Ltd. approved the cash dividend of CNY 0.1000000 per ten shares (tax included) for the year 2020. Record date is 03 June 2021. Ex-date is 04 June 2021. Payment date is 04 June 2021.

Latest news about Hubei Biocause Pharmaceutical Co., Ltd.

Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 29	CI
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 15	CI
Biocause Pharma’s Insurance Unit Posts Steady Annual Premium in 2023	Jan. 15	MT
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-30	CI
Hubei Biocause Pharmaceutical Co., Ltd. agreed to acquire 60% stake in Huarui Insurance Sales Co.,Ltd. for approximately CNY 150 million.	23-09-21	CI
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-30	CI
Biocause Pharma Unit Logs 31 Million Yuan Insurance Premium Income in January-July Period	23-08-14	MT
Biocause Pharma Unit Generates 24 Billion Yuan Premium Income in January-May Period	23-06-12	MT
Hubei Biocause Pharmaceutical Co., Ltd. Approves Final Cash Dividend for the Year 2022, Payable on 30 May 2023	23-05-22	CI
Biocause Pharma’s Life Insurance Unit Generates 22 Billion Yuan in January-April Premium Income	23-05-16	MT
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
Hubei Biocause Pharmaceutical Co., Ltd. Announces Final Profit Distribution Proposal for 2022	23-04-24	CI
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-14	CI
Hubei Biocause Pharmaceutical Gets Regulatory Nod for Ibuprofen; Shares Down 5%	22-12-30	MT
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-28	CI
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-29	CI
Biocause Heilen Pharma to Unlock 1.21% Restricted Stake	22-06-19	MT
Hubei Biocause Pharmaceutical Co., Ltd. Approves Cash Dividend for 2021, Payable on June 2, 2022	22-05-24	CI
Hubei Biocause Pharmaceutical Co., Ltd. Proposes Cash Dividend for 2021	22-05-05	CI
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-29	CI
Hubei Biocause’s Pharmaceutical Ingredients Unit Surges 64% in Shenzhen Debut	21-12-21	MT
Hubei Biocause’s Pharmaceutical Ingredients Unit Targets $243 Million in Shenzhen IPO	21-12-09	MT
Hubei Biocause’s Pharmaceutical Ingredients Unit Launches Shenzhen IPO	21-12-02	MT
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-29	CI
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-30	CI

Chart Hubei Biocause Pharmaceutical Co., Ltd.

Duration

Period

Chart Hubei Biocause Pharmaceutical Co., Ltd.

More charts

Company Profile

Hubei Biocause Pharmaceutical Co.,Ltd. is a China-based company principally engaged in insurance business, such as life insurance, health insurance and casualty insurance. The Company is also involved in pharmaceutical business and chemical business. The Companyâs products include polypropylene and Ibuprofen. The Company distributes its products in domestic market and to overseas markets, with Central China and South China as its main markets.

Sector

Life & Health Insurance

Calendar

2024-05-24 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Life & Health Insurance

	1st Jan change	Capi.
HUBEI BIOCAUSE PHARMACEUTICAL CO., LTD.	-18.66%	1.58B
AXA	+14.34%	79.9B
METLIFE, INC.	+9.98%	51.72B
AFLAC INCORPORATED	+4.34%	48.91B
MANULIFE FINANCIAL CORPORATION	+21.58%	46.79B
PRUDENTIAL FINANCIAL, INC.	+14.58%	42.67B
GENERALI	+27.72%	40.79B
SUN LIFE FINANCIAL INC.	-0.31%	29.14B
GREAT-WEST LIFECO INC.	-1.32%	29.55B
PRUDENTIAL PLC	-9.63%	27.5B

Other Life & Health Insurance